Literature DB >> 24090894

[Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].

C Girard1, T Vincent, D Bessis.   

Abstract

BACKGROUND: A new antibody known as anti-MDA-5 has recently been identified in association with a specific phenotype of dermatomyositis (DM), in which muscular involvement is minimal or absent, but where there is a particularly high risk of onset of aggressive interstitial lung disease. Below, we report a case associated with the presence of anti-MDA-5 antibodies complicated by aggressive interstitial lung disease ; the cutaneous phenotype of this patient is novel due to the constitution of diffuse ichthyosis and of profuse subcutaneous calcinosis. PATIENTS AND METHODS: A 35-year-old man was hospitalised for a skin rash associated with arthralgia, dry cough, asthenia and weight-loss of 8 kg in 5 months. The dermatological examination revealed purple erythema of the upper eyelids and cheeks, diffuse acquired ichthyosis of the trunk and limbs, and striated erythema on the proximal and distal metacarpal and interphalangeal joints of the fingers. A diagnosis of DM was suspected in patients treated with prednisolone, 1.5 mg/kg/d. Immunological tests identified the presence of anti-MDA-5 antibodies. One month later, the cutaneous signs continued to progress and were marked by the development of painful ulcers on the back of the fingers, as well as dyspnoea accompanying the slightest effort. Chest images showed constituted pulmonary fibrosis lesions. At the same time, within several months, diffuse, pseudo-tumoural calcifications developed in the subcutaneous tissue of the trunk and limbs. The patient was treated successively with intravenous gammaglobulins, cyclophosphamide, mycophenolate mofetil, azathioprine and rituximab in combination with oral corticosteroids, but with no improvement in respiratory function or in the skin lesions. Because of the decline in the patient's respiratory status, a lung graft was envisaged but subsequently abandoned because of the patient's excessively precarious state of health. DISCUSSION: Anti-MDA-5 antibody appears to constitute a specific immunological marker for a special dermatological phenotype of adult DM, significantly associated with the presence of: 1) keratotic papules in the skin folds of the palms and fingers ; 2) cutaneous ulcers along the periungueal edges, Gottron's papules on the back of the hands and on the extensor surface of the elbows and knees ; 3) pain and ulceration in the oral mucosa, diffuse alopecia, and appearance of "mechanic's hands" and Gottron's sign on the elbows and knees. To our knowledge, the presence of extensive ichthyosis and profuse subcutaneous calcinosis has not been previously reported in this particular form of DM. The risk of aggressive interstitial lung disease is particularly high and worsens the prognosis, since 40% of patients with anti-MDA-5 die, usually within the first year.
CONCLUSION: Herein, we describe a patient presenting amyopathic DM complicated by aggressive interstitial lung disease associated with the presence of anti-MDA-5 antibodies, but with a hitherto unreported cutaneous phenotype combining diffuse ichthyosis and profuse subcutaneous calcinosis.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acquired ichthyosis; Anticorps MDA-5; Dermatomyosite; Dermatomyositis; Ichtyose acquise; Interstitial lung disease; MDA-5 antibodies; Pneumopathie interstitielle

Mesh:

Substances:

Year:  2013        PMID: 24090894     DOI: 10.1016/j.annder.2013.04.083

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  6 in total

1.  Is rituximab an effective treatment of refractory calcinosis?

Authors:  Maria Dubos; Kim Ly; Clothilde Martel; Anne Laure Fauchais
Journal:  BMJ Case Rep       Date:  2016-05-31

Review 2.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Authors:  Roberta Vilela Lopes Koyama; Tiago Kiyoshi Kitabayashi Braga; George Alberto da Silva Dias; Satomi Fujihara; Hellen Thais Fuzii; Gilberto Toshimitsu Yoshikawa
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

Review 3.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 4.  Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Gian Luca Erre; Carlo Salvarani; Andreina Manfredi
Journal:  Drugs Context       Date:  2021-01-15

5.  Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis.

Authors:  Houari Aissaoui; Kinan Drak Alsibai; Naji Khayath
Journal:  Clin Pract       Date:  2021-04-22

6.  Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.

Authors:  Chenjia He; Wenyu Li; Qibing Xie; Geng Yin
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.